Brodalumab在肥胖与非肥胖银屑病患者中的疗效与安全性相当:两项随机对照试验分析
本文为AMAGINE-2和AMAGINE-3两项III期随机对照试验的事后分析,评估brodalumab在肥胖(BMI≥30 kg m⁻²)与非肥胖(BMI<30 kg m⁻²)中重度银屑病患者中的疗效与安全性。结果显示brodalumab的疗效与安全性在两组间无显著差异,而ustekinumab在肥胖患者中的应答较低。
要点
- brodalumab在肥胖与非肥胖银屑病患者中疗效相当。
- brodalumab总体安全性在肥胖与非肥胖患者间无显著差异。
- ustekinumab在肥胖患者中的应答较非肥胖患者低6-17%。
核心结论
- brodalumab在中重度银屑病患者中,BMI<30 kg m⁻²与BMI≥30 kg m⁻²两组的疗效和安全性无差异。
研究设计与样本
- 本文为AMAGINE-2和AMAGINE-3两项前瞻性、III期、多中心、随机、安慰剂和阳性对照对照试验的事后分析。
- 患者随机接受brodalumab 210 mg每2周、ustekinumab或安慰剂治疗12周诱导期,第12周后安慰剂组换用brodalumab 210 mg每2周。
主要发现
- ustekinumab第12周应答低于brodalumab,且肥胖患者较非肥胖患者低6-17%。
- 非肥胖与肥胖患者总体安全性无显著差异。
临床怎么用
- brodalumab可作为中重度银屑病肥胖患者的治疗选择,无需因BMI调整预期疗效或安全性监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is associated with psoriasis and negatively affects response to therapy. OBJECTIVES: To evaluate the efficacy and safety of brodalumab in nonobese vs. obese patients with psoriasis. METHODS: This is a post hoc analysis of the prospective, phase III, multicentre, randomized, placebo- and active-comparator-controlled AMAGINE-2 and AMAGINE-3 trials, in which patients were randomized to treatment with brodalumab 210 mg every 2 weeks, ustekinumab or placebo for a 12-week induction phase. At week 12, patients who received brodalumab 210 mg every 2 weeks continued brodalumab, those treated with ustekinumab continued ustekinumab, and those who received placebo switched to brodalumab 210 mg every 2 weeks. Patients were categorized by body mass index (BMI) category (< 30 or ≥ 30 kg m-2 ) and efficacy was evaluated using the physician-rated Psoriasis Area and Severity Index and static Physician's Global Assessment instruments. RESULTS: In total, 281 of 687 patients (40·9%) were obese. Skin clearance was comparable across BMI subgroups in brodalumab-treated patients. Psoriasis Area and Severity Index 100% improvement rates in nonobese and obese patients at week 12 were 54·1% and 49·5%, respectively, and at week 52 they were 72·6% and 64·8%, respectively. Week 12 ustekinumab responses were lower than brodalumab responses and were 6-17% lower in obese than in nonobese patients. No appreciable differences in overall safety were observed between nonobese and obese patients. CONCLUSIONS: The efficacy and safety of brodalumab did not differ between patients with moderate-to-severe psoriasis who had a BMI < 30 kg m-2 or a BMI ≥ 30 kg m-2 .
引用
- Hsu S, Green LJ, Lebwohl MG, et al. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. Br J Dermatol. 2019. PMID: 31276189. doi:10.1111/bjd.18327
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。